Comprehensive genomic profiling identifies novel genetic predictors of response to anti–PD-(L) 1 therapies in non–small cell lung cancer
Purpose: Immune checkpoint inhibitors (ICI) have revolutionized cancer management.
However, molecular determinants of response to ICIs remain incompletely understood�…
However, molecular determinants of response to ICIs remain incompletely understood�…
Integration of comprehensive genomic profiling, tumor mutational burden, and PD‐L1 expression to identify novel biomarkers of immunotherapy in non‐small cell lung�…
Y Shi, Y Lei, L Liu, S Zhang, W Wang, J Zhao…�- Cancer�…, 2021 - Wiley Online Library
Objectives This study aimed to explore the novel biomarkers for immune checkpoint inhibitor
(ICI) responses in non‐small cell lung cancer (NSCLC) by integrating genomic profiling�…
(ICI) responses in non‐small cell lung cancer (NSCLC) by integrating genomic profiling�…
Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non‐small cell lung cancer
I Alborelli, K Leonards, SI Rothschild…�- The Journal of�…, 2020 - Wiley Online Library
In non‐small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs) significantly
improve overall survival (OS). Tumor mutational burden (TMB) has emerged as a predictive�…
improve overall survival (OS). Tumor mutational burden (TMB) has emerged as a predictive�…
[HTML][HTML] The role of molecular profiling to predict the response to immune checkpoint inhibitors in lung cancer
C Kaderbha�, Z Tharin, F Ghiringhelli�- Cancers, 2019 - mdpi.com
Immune checkpoint inhibitors radically changed the treatment of patients with non-small cell
lung cancer (NSCLC). However, only one-quarter of patients benefit from these new�…
lung cancer (NSCLC). However, only one-quarter of patients benefit from these new�…
[HTML][HTML] Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
Background Resistance to immune checkpoint inhibitors (ICIs) has been linked to local
immunosuppression independent of major ICI targets (eg, PD-1). Clinical experience with�…
immunosuppression independent of major ICI targets (eg, PD-1). Clinical experience with�…
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are
revolutionizing cancer treatment. To unravel the genomic determinants of response to this�…
revolutionizing cancer treatment. To unravel the genomic determinants of response to this�…
[HTML][HTML] Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer
Combination immune checkpoint blockade has demonstrated promising benefit in lung
cancer, but predictors of response to combination therapy are unknown. Using whole-exome�…
cancer, but predictors of response to combination therapy are unknown. Using whole-exome�…
[HTML][HTML] Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study
X Bai, DH Wu, SC Ma, J Wang, XR Tang…�- …�for immunotherapy of�…, 2020 - ncbi.nlm.nih.gov
Background Genetic variations of some driver genes in non-small cell lung cancer (NSCLC)
had shown potential impact on immune microenvironment and associated with response or�…
had shown potential impact on immune microenvironment and associated with response or�…
[HTML][HTML] HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L) 1 blockade in advanced non-small�…
Background Immune checkpoint inhibitors (ICIs) have been shown to be beneficial for some
patients with advanced non-small-cell lung cancer (NSCLC). However, the underlying�…
patients with advanced non-small-cell lung cancer (NSCLC). However, the underlying�…
[HTML][HTML] The clinical utility of tumor mutational burden in non-small cell lung cancer
L Greillier, P Tomasini, F Barlesi�- Translational lung cancer�…, 2018 - ncbi.nlm.nih.gov
Despite advances made during the last two decades, lung cancer remains the leading
cause of cancer-related death worldwide. Recently, immune checkpoint inhibitors (ICIs)�…
cause of cancer-related death worldwide. Recently, immune checkpoint inhibitors (ICIs)�…